Trial description:
A phase 2, open-label, single-arm trial of Trastuzumab Deruxtecan (DS-8201A) in HER2-positive, unresectable ormetastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a Trastuzumab containing regime
Contact name:
Dr Lizzie Smyth
Trial start date:
Friday, December 13, 2019
Trial end date:
Friday, April 1, 2022
Trial tumour type:
Oesophageal
Show on Radiotherapy:
No
